Clinical Trial Update: Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations [Phase 1]

View source ↗

Summary

This Phase 1 study compares how two subcutaneous presentations of Maridebart Cafraglutide (AMG 133) affect systemic drug exposure in individuals with overweight…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Maridebart Cafraglutide (AMG 133) (cafraglutide)

Snippet

Sponsor: Amgen | Conditions: Overweight, Obesity | Phase 1 | Status: ACTIVE_NOT_RECRUITING